GlassScriptPhysician profile
Amanda K Payne
NPI 1386060218
$4,275.97
in general payments reported to CMS, 2019-2025
29 companies · $863 in 2025
The $863 reported for 2025 was more than what 94% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $925 · 2022: $946 · 2023: $1,022 · 2024: $521 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $458.76 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $378.69 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $360.72 | 2021-2025 | |
| Pfizer INC. | $327.96 | 2021-2025 | |
| Abbvie INC. | $324.06 | 2021-2023 | |
| Organon LLC | $317.90 | 2021-2025 | Nexplanon, Jada System |
| Mayne Pharma Commercial LLC | $294.95 | 2021-2025 | |
| Exeltis, USA INC. | $289.68 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $237.74 | 2021-2022 | |
| Biogen, INC. | $196.01 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $171.61 | 2023-2025 | Accrufer |
| Evofem Biosciences, INC. | $157.91 | 2021-2022 | |
| Hologic Sales and Service, LLC | $120.66 | 2023-2025 | Thinprep 2000 Processor, Aptima |
| Avion Pharmaceuticals | $86.06 | 2021-2022 | |
| Aspira Women'S Health INC | $70.67 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $65.38 | 2023 | Myrisk |
| Lsi Solutions INC | $58.19 | 2025 | Fornisee |
| Therapeuticsmd, INC. | $47.91 | 2021-2022 | |
| Gynesonics, INC. | $47.25 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Scynexis, INC. | $43.23 | 2022 | |
| Agile Therapeutics, INC. | $43.21 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $38.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.80 | 2021-2023 | Gardasil 9 |
| Becton, Dickinson and Company | $30.33 | 2022 | |
| Medtronic, INC. | $16.65 | 2022 | |
| Urovant Sciences INC | $14.59 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.67 | 2023 | Monoferric |
| Kowa Pharmaceuticals America, INC. | $13.60 | 2023 | Seglentis |
| Coloplast Corp | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.